Home > About Primary Immunodeficiency (PI) > Diagnosis

PI Diagnosis

Types and Causes of PI

Some of the more common types of primary immunodeficiency (PI) include selective IgA deficiency, common variable immune deficiency (CVID), X-linked agammaglobulinemia (XLA), and severe combined immunodeficiency (SCID).1

PI is different from secondary immunodeficiencies, which are caused by other conditions (such as diseases or consequence of medication use), whereas PI is caused by a defect in the immune system, and can be inherited.1

There's relief with diagnosis.

Charlotte, diagnosed at age 38

How Common Is PI?

Primary immunodeficiency was once thought to be very rare, but now it is considered more common. As PI awareness with physicians continues to grow, more people are getting diagnosed.1 In a 2007 Immune Deficiency Foundation survey, it was estimated that a quarter million people in the United States have been diagnosed with PI,2 and the U.S. National Institutes of Health estimate that ~500,000 cases of PI remain undiagnosed.3

Testing for PI

When testing for PI, doctors will typically ask about your family history and do a physical exam. They may order blood tests to check if your red and white blood cells, antibodies, and immune system are working properly. These tests are important for your doctor to confirm a diagnosis of PI.1

If you have been diagnosed, these tests help determine which type of PI you may have. Once the tests are complete, and the PI diagnosis is confirmed, your doctor will recommend the best treatment options for your specific type of PI.

Early Diagnosis Is Important

If left untreated, chronic infections caused by PI can lead to organ damage, such as lung damage.1 People whose PI is discovered later in life may already have some permanent organ damage from previous infections. Immunoglobulin (Ig) replacement treatment cannot reverse any existing damage, but can reduce the number of infections.1

What Can I Do About PI?

If you have PI, there are medicines that can help. Keep reading to learn more about PI and your treatment options, and talk to your healthcare provider about what's right for you.

References: 1. Blaese RM, Bonilla FA, Stiehm ER, Younger ME, eds. Patient & Family Handbook for Primary Immunodeficiency Diseases. 5th ed. Towson, MD: Immune Deficiency Foundation; 2013. 2. Boyle JM, Buckley RH. Population prevalence of diagnosed primary immunodeficiency diseases in the United States. J Clin Immunol. 2007;27(5):497-502. 3. Modell F, Puente D, Modell V. From genotype to phenotype. Further studies measuring the impact of a Physician Education and Public Awareness Campaign on early diagnosis and management of primary immunodeficiencies. Immunol Res. 2009;44(1-3):132-149.

  • MyIgSource is a patient support program for all PI patients and caregivers throughout your journey. Sign up to get access to experienced Patient and Nurse Advocates, get information about insurance and financial support, useful tools, and more.
    Learn More
  • Ask an Advocate Questions about PI or PI treatments? Our trained Patient and Nurse Advocates can help, and asking your question is easy with our Ask An Advocate feature.
    Start Getting Answers

Gammagard Liquid MyIgCoPayCard Program Terms and Conditions

This manufacturer's coupon program is not valid for prescriptions reimbursed, in whole or in part, by Medicaid, Medicare, Medigap, VA, DoD, TRICARE, or any other federal or state healthcare programs, including state pharmaceutical assistance programs, and where prohibited by the health insurance provider or by law

Shire's MyIgCoPayCard program provides a maximum total benefit of $5,000 for eligible out-of-pocket costs and expires 12 months from date of activation. Eligible costs include deductible, copayment, and co-insurance costs for eligible Shire IG (Immunoglobulin) products. Non-medication expenses, such as ancillary supplies or administration-related costs, are not eligible.

To be eligible, patients must: 1. be starting or receiving treatment with (and have current prescription for) an eligible Shire IG product with an ICD-10 for a diagnosis of Primary Immunodeficiency; and 2. have commercial insurance that covers medication costs for prescribed Shire IG product and allows for CoPay assistance; and 3. be two (2) years old or older.

Acceptance of this offer must be consistent with the terms of benefits provided by patient's health insurance provider.

Offer limited to one card per person and may not be combined with any other coupon, discount, prescription savings card, rebate, free trial, patient assistance, or other offer.

This program is only valid for residents of the United States.

Shire reserves the right to change or discontinue this program at any time without notice.

This is not health insurance.


Add to patient instructions:

If your insurance situation changes, it is your responsibility to notify MyIgSource's CoPay assistance program.

© 2017 Shire. All rights reserved.

SHIRE and the Shire Logo are registered trademarks of Shire Pharmaceutical Holdings Ireland Limited or its affiliates. Gammagard Liquid is a trademark or registered trademark of Baxalta Incorporated, a wholly owned, indirect subsidiary of Shire plc.

S30515 04/17

Please expand for Indication and Important Safety Information.


What is the most important information that I should know about GAMMAGARD LIQUID?

GAMMAGARD LIQUID can cause the following serious reactions: severe allergic reactions causing difficulty in breathing or skin rashes; decreased kidney function or kidney failure; blood clots in the heart, brain, lungs or elsewhere in the body; severe headache, drowsiness, fever, painful eye movements, or nausea and vomiting; dark colored urine, swelling, fatigue, or difficulty breathing.